HEPATOCELLULAR CARCINOMA (HCC)

This study tests a combination of two drugs—tislelizumab (an immunotherapy) and huaier granule (a traditional Chinese medicine)—as the first treatment for people with liver cancer that cannot be removed by surgery. About 94 adults will receive this combination to see if it shrink…

This study tests whether giving chemotherapy directly into the liver after surgery can prevent liver cancer from returning in patients at high risk of recurrence. About 30 adults who recently had their liver cancer removed will receive a special chemo cocktail through a tube into…

This study tests whether adding Icaritin soft capsules to standard liver infusion chemotherapy can help prevent liver cancer from returning after surgery. It involves 30 adults with high-risk liver cancer who have recently had their tumor removed. The goal is to see if this combi…

This study tests whether adding a liver-directed chemotherapy infusion (HAIC) to a two-drug immunotherapy regimen (sintilimab plus bevacizumab) can better control advanced liver cancer. About 164 adults with advanced liver cancer who have not had prior systemic therapy will be ra…

This study tests whether a computer guidance tool can help doctors more completely destroy liver tumors during a microwave ablation procedure. About 84 adults with liver cancer will have their tumor treated using this software, which shows a simulation of the treated area in real…

This early-phase study tests an experimental oral drug called ST-01156 in people with advanced solid tumors (including Ewing sarcoma, liver cancer, and bile duct cancer) that have not responded to standard treatments. The drug works by breaking down a protein (RBM39) that cancer …

This study tests whether adding three immunotherapy drugs to a standard liver cancer procedure (TACE) can shrink tumors better than TACE alone. About 36 adults with advanced liver cancer will be randomly assigned to one of three treatment groups. The goal is to find a safer, more…

This study tests two new drugs: one to spot liver cancer cells and another to deliver radiation directly to them. It is for adults with a type of liver cancer that cannot be removed by surgery and has worsened after one prior treatment. The goal is to see if the treatment shrinks…

This study tests a new approach for people with locally advanced liver cancer that is hard to remove with surgery alone. Participants will receive two immunotherapy drugs (ipilimumab and nivolumab) along with targeted radiation, followed by surgery if the tumor shrinks enough. Th…

This study tests a personalized mRNA vaccine (iNeo-Vac-R01) made from a patient's own tumor, given together with an immunotherapy drug (PD-1 inhibitor) after liver cancer surgery. The goal is to train the immune system to destroy any remaining cancer cells and prevent the cancer …

This study tests a faster way to treat small liver cancers (up to 5 cm) using tiny radioactive beads called Y90 resin microspheres. Normally, doctors do a pre-treatment scan to check where the beads will go, but this study skips that step for patients who meet certain safety crit…

This study is for people with advanced liver cancer who are starting a combination of two drugs (atezolizumab and bevacizumab). It will test if adding a procedure called TIPS, which places a small tube in the liver to improve blood flow, helps keep the liver working better for lo…

This study tests whether combining radiation therapy with an immunotherapy drug (sintilimab) is better than a standard liver-directed treatment (TACE) at preventing liver cancer from returning after surgery. It includes 286 adults whose tumors were removed but had narrow margins …

This study tests a DNA vaccine called NWRD06 in 30 adults with a type of liver cancer (hepatocellular carcinoma) that has been surgically removed. The vaccine targets a protein called GPC3 found on cancer cells, aiming to train the immune system to destroy any remaining cancer an…

This early-stage study tests a new drug called CREPT-618 in 13 adults with advanced liver cancer that has not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. Researchers will also look at how the drug moves through the body an…

This study tests whether giving a combination of two drugs (apatinib and camrelizumab) along with a procedure called TACE before liver surgery can shrink tumors and lower the chance of cancer coming back. It involves 27 adults with a specific type of liver cancer that can be remo…

This early-phase study tests a new drug called CBA-1205, an antibody that targets a protein (DLK1) found on some cancer cells. The main goal is to check the drug's safety and find the right dose in about 66 adults with advanced solid tumors, including liver cancer and melanoma. P…

This study tests whether combining a liver-directed procedure (TACE) with the drug icaritin can help prevent liver cancer from returning after surgery in patients at high risk of recurrence. About 30 adults who recently had their liver cancer completely removed will receive this …

This study is for people with advanced liver cancer whose disease got worse after standard first-line treatment with atezolizumab and bevacizumab. Researchers want to see if adding chemotherapy (FOLFOX) to the same two drugs can shrink tumors or slow the cancer. About 30 adults w…

This program provides early access to two investigational immunotherapy drugs, botensilimab and balstilimab, for people with serious or life-threatening cancers such as colorectal, pancreatic, lung, liver, melanoma, sarcoma, ovarian, or prostate cancer. It is for patients who hav…

This study tests a four-part treatment plan for people with advanced liver cancer that cannot be surgically removed. The plan includes chemotherapy directly into the liver, two drugs (durvalumab and bevacizumab), and targeted radiation. The goal is to shrink the tumors enough so …

This study compares two types of chemoembolization (TACE) for liver cancer patients whose cancer has spread beyond standard transplant criteria and who have previously had a TIPS procedure to manage complications of cirrhosis. About 206 participants will be randomly assigned to r…

This study tests whether a same-day procedure using Y90 resin microspheres is safe and feasible for people with large liver tumors (over 5 cm). About 138 participants will receive planning angiography, a scan, and treatment all in one day. The goal is to confirm that this approac…

This early-stage study tests a new drug called Sapu003 in people with advanced cancers that are sensitive to mTOR treatment, including certain breast cancers, kidney cancer, and liver cancer. The main goal is to find the safest dose and understand side effects. About 27 adults wi…

This study is testing a new drug called CTX-10726 in people with advanced cancers (stomach, liver, endometrial, or kidney) that have not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. About 70 participants will receive the dr…

This study tests a combination of two drugs, IBI310 and sintilimab, in people with advanced liver cancer that cannot be removed by surgery. The goal is to see if the combo can shrink tumors or slow cancer growth better than current treatments. About 680 adults who have not had pr…

This study tests a copycat version (HLX13) of an approved cancer drug (YERVOY) in adults with advanced liver cancer that cannot be removed by surgery. About 246 people will receive either the copycat or the original drug to see if they work similarly. The goal is to control the c…

This study tests whether a combination of two drugs (sintilimab and bevacizumab biosimilar) can help prevent liver cancer from coming back after surgery in people whose tumor had ruptured. About 35 adults with this high-risk condition will receive the treatment. The goal is to se…

This study compares two types of radiation therapy (SBRT and SIRT) combined with immunotherapy for people with advanced liver cancer that cannot be surgically removed. About 106 participants will be randomly assigned to one of two treatment arms. The goal is to see which approach…

This early-stage trial tests a new drug called XL092, alone or with other immune-boosting drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors or slow their gro…

This study tests whether giving a drug called polyene phosphatidylcholine before and after laparoscopic liver surgery can reduce liver damage in people with liver cancer. About 96 adults will be split into two groups: one gets the drug combo, the other gets standard care. The mai…

This study tests a combination of two experimental drugs (AK104/AK112 and TT-00420) in 100 adults with advanced liver cancer that cannot be treated with surgery. The goal is to see if the drugs can shrink tumors and control the disease. Participants must not have had prior cancer…

This study tests a new drug called ABSK-011 for people with advanced liver cancer that has not responded to previous treatments. The drug targets a specific protein (FGF19) found in some tumors. About 141 participants will receive either ABSK-011 or a placebo, both with standard …

This study tests a new drug called pumitamig, either alone or with another drug (ipilimumab), in people with advanced liver cancer that cannot be removed by surgery. About 129 participants will receive the treatment to see if it is safe and helps shrink tumors. The goal is to con…

This study tests a new way to do PET scans that uses two different tracers at the same time to get more detailed images of liver cancer and pancreatic tumors. Researchers want to see if this method is safe and finds more tumors than standard single-tracer scans. About 28 adults w…

This study is developing a blood test that looks for tiny molecules called miRNAs to detect several types of digestive system cancers (like liver, pancreatic, and colon cancer) early. The goal is to create a simple, noninvasive screening tool that can be used for large population…

This study aims to develop a blood test that can detect liver cancer (hepatocellular carcinoma) at an early stage, when treatment is more likely to work. Researchers will analyze tiny genetic particles in the blood of 600 people already diagnosed with liver cancer to see if these…

This study is developing a computer system that uses CT scans and artificial intelligence to predict whether liver cancer has started to invade nearby blood vessels, a condition called microvascular invasion. Currently, this can only be confirmed after surgery by examining remove…

This study tests a new radioactive tracer called 89Zr-TLX250 to see if it can better detect liver cancer, bile duct cancer, and certain neuroendocrine tumors on PET-CT scans. The tracer targets a protein (CAIX) found on these cancer cells. Researchers will compare the number and …

This study is testing a new type of PET/CT scan that uses a special tracer called 18F-T2 to find cancers that have high levels of a protein called CAIX. About 200 adults with cancers like kidney, bladder, lung, or breast cancer will get this scan to see if it works better than th…

This study is testing whether offering liver cancer screening every 6 months to people with cirrhosis can reduce deaths from liver cancer. The screening includes an ultrasound and a blood test. About 617 adults aged 40-79 with compensated cirrhosis in one region of Denmark will b…

This study tests whether a smartphone app that lets liver cancer patients regularly report their symptoms can improve their quality of life during immunotherapy. 500 adults with liver cancer will either use the app to get personalized advice and alerts or receive standard care. T…

This study looks at whether a patient's emotional state—like depression or anxiety—can influence how well advanced liver cancer responds to a combination of chemotherapy, targeted therapy, and immunotherapy. Researchers will follow 90 adults with BCLC stage B or C liver cancer, g…

This study is looking at whether certain substances in the blood can help doctors predict how well a liver cancer treatment called TACE is working. Researchers will follow 15 adults with liver cancer who are scheduled for TACE. They will take blood samples before and after treatm…

This study is testing whether a blood test (liquid biopsy) can predict how well liver cancer responds to a type of internal radiation therapy called Y90 radioembolization. Researchers will take blood samples from 12 adults with liver cancer before and after treatment to look for …

This study looks at whether an artificial intelligence (AI) tool can help doctors more accurately stage and choose treatments for liver cancer. About 108 adults with suspected or newly diagnosed liver cancer will take part. Doctors will make decisions both with and without AI hel…

This study looks at 600 adults with liver cirrhosis to see how well ultrasound and a shorter MRI scan find early liver cancer. Researchers will also track body composition and other health changes over time. The goal is to find better ways to monitor patients and predict who is a…

This study aims to improve a liver cancer treatment called TARE, which delivers radiation directly to tumors through blood vessels. Researchers will create computer models of each patient's liver blood flow to predict where the radiation goes. The goal is to help doctors plan tre…

This study involves 30 adults with liver tumors who are scheduled for radioembolization, a treatment that delivers radiation directly to the tumor. Doctors want to see if using a small 'scout dose' of the actual treatment beads can more accurately measure how much radiation might…